The grades of four Biotechnology stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an “A” (“strong buy”) or “B” overall (“buy”) rating.
ChemoCentryx Inc (NASDAQ:CCXI) is bumping up its rating from a C (“hold”) to a B (“buy”) this week. ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine syste… For more information, get Portfolio Grader’s complete analysis of CCXI stock.
The rating of Incyte Corp. (NASDAQ:INCY) moves up this week, rising from a C to a B. Incyte is using its expertise in genomics and medicinal chemistry, as well as molecular, cellular, and in vivo biology to discover and develop novel therapeutics. Shares of INCY have increased 14.7% over the past month, better than the 2.5% increase the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of INCY stock.
Opko Health (NYSE:OPK) is seeing ratings go up from a C last week to a B this week. OPKO Health is involved in the discovery, development, and commercialization of pharmaceutical products, vaccines, and diagnostic products. Investors have pushed the stock price up 6.2% over the past month. For more information, get Portfolio Grader’s complete analysis of OPK stock.
Biogen Idec (NASDAQ:BIIB) is progressing from last week’s rating of B (“buy”) as the company improves to an A (“strong buy”) this week. Biogen Idec is a global biotechnology company that meets the needs of therapeutic care providers and recipients. Wall Street has pushed the stock higher by 16.5% over the past month. For more information, get Portfolio Grader’s complete analysis of BIIB stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
